Clinical trial
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond…
NCT00229619 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00229619 |
|---|---|
| Title | Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia |
| Official title | A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Aplastic, Red-Cell Aplasia, Pure, Diamond-Blackfan |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 11 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Sep 29, 2005 |
| Last update posted | Sep 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: